title: Therapeutic application of intrapericardial tissue plasminogen activator in a 4-month-old child with complex fibropurulent pericarditis.
abstract: OBJECTIVE
  To describe a young child with complex fibropurulent pericarditis who was successfully treated with intrapericardial recombinant tissue plasminogen activator.
  
  
  METHODS
  Individual case report.
  
  
  METHODS
  Pediatric intensive care unit of a tertiary children's hospital.
  
  
  METHODS
  A 4-month-old Asian girl with Staphylococcus aureus septic shock who later developed a loculated fibropurulent pericardial effusion that was refractory to management with a subxiphoid percutaneous pericardial drainage catheter.
  
  
  METHODS
  Three doses of intrapericardial tissue plasminogen activator were administered at 12-hr intervals, allowed to dwell for 2 hrs, and subsequently drained via low continuous suction.
  
  
  RESULTS
  Immediately after intrapericardial tissue plasminogen activator was administered via a percutaneous pericardial drainage catheter, the patient had an increase in pericardial fluid drainage and resolution of a complex fibropurulent pericardial effusion. Pericardial fluid drainage ceased and then increased to 122 mL, 270 mL, and 80 mL of fluid, respectively, after each of the three doses of intrapericardial tissue plasminogen activator. Serial echocardiography confirmed the initial presence of the effusion, the subsequent loculated nature of the effusion, and ultimate resolution of the effusion after tissue plasminogen activator. The patient survived to hospital discharge without cardiac dysfunction.
  
  
  CONCLUSIONS
  The fibrinolytic effect of tissue plasminogen activator therapy promotes the resolution of complex fibropurulent pericardial effusions refractory to traditional pericardial drainage via percutaneous catheter and suction. Use of intrapericardial tissue plasminogen activator may preclude the need for surgical intervention in fibropurulent pericarditis.
authors.affiliation: Department of Pediatrics, Division of Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229-3039, USA. michael.bigham@cchmc.org
authors.forename: Michael T
authors.initials: MT
authors.lastname: Bigham
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Brady
authors.forename: Peter B
authors.initials: PB
authors.lastname: Manning
authors.forename: Brian R
authors.initials: BR
authors.lastname: Jacobs
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Kimball
authors.forename: Hector R
authors.initials: HR
authors.lastname: Wong
mesh_terms: D004452:Echocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005355:Fibrosis; D006801:Humans; D007223:Infant; D015278:Intensive Care Units, Pediatric; D010490:Pericardial Effusion; D010493:Pericarditis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D010496:Pericardium / Q000187:drug effects; D013203:Staphylococcal Infections / Q000150:complications / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator